Exelixis Inc (EXEL)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$36.19
Buy
$37.10
$-0.33 (-0.90%)
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
Prices updated at 10 May 2025, 00:17 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Stelios Papadopoulos,PhD
CEO
Dr. Michael M. Morrissey, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,147
Head office
1851 Harbor Bay Parkway
Alameda
United States
94502
Key personnel
Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
---|---|---|---|---|---|
Dr. George H. Poste, D.V.M.,F.R.S.,PhD Independent Director | 0.10m | - | - | 0.51m | - |
Mr. Jack L. Wyszomierski, M.S. Independent Director | 0.10m | - | - | 0.51m | - |
Dr. Michael M. Morrissey, PhD Director, President and Chief Executive Officer | 1.25m | - | - | 12.73m | - |
Dr. Stelios Papadopoulos,PhD Chairman of the Board | 0.13m | - | - | 0.54m | - |
Mr. David E. Johnson Independent Director | 0.09m | - | - | 0.49m | - |
Dr. Mary C. Beckerle, PhD Independent Director | 0.08m | - | - | 1.16m | - |
Dr. Maria C. Freire, PhD Independent Director | 0.10m | - | - | 0.51m | - |
Ms. Julie Anne Smith Independent Director | 0.10m | - | - | 0.51m | - |
Mr. Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary | 0.65m | - | - | 4.45m | - |
Mr. Christopher J. Senner Executive Vice President, Chief Financial Officer and Principal Accounting Officer | 0.79m | - | - | 4.68m | - |
Dr. Amy C. Peterson, M.D. Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer | 0.65m | - | - | 4.45m | - |
Mr. Patrick J. Haley Executive Vice President, Commercial | - | - | - | - | - |
Mr. Tomas J. Heyman Independent Director | 0.09m | - | - | 0.50m | - |
Dr. Sue Gail Eckhardt, M.D. Independent Director | 0.08m | - | - | 1.16m | - |
Dr. Dana T. Aftab, PhD Chief Scientific Officer and Executive Vice President, Discovery and Translational Research | 0.62m | - | - | 3.90m | - |
Mr. Robert Oliver, M.B.A. Independent Director | 0.08m | - | - | 0.49m | - |
Top 5 shareholders
Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
---|---|---|---|---|---|---|
BlackRock Inc | 30,316,051 | 0.02043 | -1760367 | -5.488041 | 30 Apr 2025 | 11.00 |
Vanguard Group Inc | 29,429,252 | 0.01707 | 121750 | 0.415423 | 30 Apr 2025 | 10.68 |
Farallon Capital Management, L.L.C. | 23,439,500 | 3.95843 | -1971000 | -7.756636 | 30 Apr 2025 | 8.51 |
BlackRock Fund Advisors | 17,684,964 | 13.6035 | -31183 | - | 30 Apr 2025 | 6.42 |
Renaissance Technologies Corp | 15,295,865 | 0.754 | -64051 | -0.417001 | 30 Apr 2025 | 5.55 |
Director dealings
Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
---|---|---|---|---|---|---|---|
20 Dec 2024 | - | Dr. Michael M. Morrissey, PhD | - | - | 736,954 | - | - |
20 Dec 2024 | - | Dr. Michael M. Morrissey, PhD | - | - | 1,587,000 | - | - |
29 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | - | - | 471,059 | - | - |
29 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | 36.67 | 2,200,200 | 486,059 | - | - |
27 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | 18.80 | 2,431,103 | 644,967 | - | - |
27 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | 35.93 | 3,553,764 | 546,059 | - | - |
27 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | - | - | - | - | - |
22 Nov 2024 | - | Mr. Patrick J. Haley | 35.27 | 352,700 | 278,665 | - | - |
15 Nov 2024 | - | Dr. Michael M. Morrissey, PhD | 35.05 | 1,669,852 | 916,742 | - | - |
15 Nov 2024 | - | Mr. Jeffrey J. Hessekiel | 35.05 | 514,254 | 515,653 | - | - |
15 Nov 2024 | - | Mr. Christopher J. Senner | 35.05 | 613,585 | 704,174 | - | - |
15 Nov 2024 | - | Dr. Amy C. Peterson, M.D. | 35.05 | 954,201 | 294,897 | - | - |
18 Nov 2024 | - | Mr. Patrick J. Haley | 34.31 | 761,922 | 308,046 | - | - |
15 Nov 2024 | - | Mr. Patrick J. Haley | 35.05 | 514,254 | 330,253 | - | - |
18 Nov 2024 | - | Mr. Patrick J. Haley | 34.41 | 666,900 | 288,665 | - | - |
15 Nov 2024 | - | Dr. Dana T. Aftab, PhD | 35.05 | 449,972 | 486,107 | - | - |
05 Nov 2024 | - | Dr. Dana T. Aftab, PhD | 18.80 | 1,823,337 | 595,931 | - | - |
05 Nov 2024 | - | Dr. Dana T. Aftab, PhD | - | - | - | - | - |
05 Nov 2024 | - | Dr. Dana T. Aftab, PhD | 35.00 | 3,394,510 | 498,945 | - | - |
01 Nov 2024 | - | Dr. George H. Poste, D.V.M.,F.R.S.,PhD | 34.00 | 1,020,000 | 169,020 | - | - |
Please note that past performance is not a reliable indicator of future returns.